

# Haluk Yuzugullu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10992136/publications.pdf>

Version: 2024-02-01

12  
papers

2,348  
citations

840776

11  
h-index

1199594

12  
g-index

12  
all docs

12  
docs citations

12  
times ranked

5677  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 1356-1369.                                    | 1.3  | 2         |
| 2  | Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. <i>Cancer Cell</i> , 2017, 31, 576-590.e8.   | 16.8 | 84        |
| 3  | NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways. <i>Cell Discovery</i> , 2016, 2, 16030.          | 6.7  | 17        |
| 4  | Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. <i>Cancer Cell</i> , 2016, 29, 255-269.  | 16.8 | 356       |
| 5  | CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. <i>Cell</i> , 2015, 163, 174-186.   | 28.9 | 346       |
| 6  | A PI3K p110 $\beta$ -Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. <i>Nature Communications</i> , 2015, 6, 8501.      | 12.8 | 44        |
| 7  | PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. <i>Nature Reviews Cancer</i> , 2015, 15, 7-24.                                 | 28.4 | 1,083     |
| 8  | Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110 $\beta$ . <i>Journal of Clinical Investigation</i> , 2014, 124, 1794-1809.          | 8.2  | 48        |
| 9  | Genome-Wide Transcriptional Reorganization Associated with Senescence-to-Immortality Switch during Human Hepatocellular Carcinogenesis. <i>PLoS ONE</i> , 2013, 8, e64016. | 2.5  | 61        |
| 10 | Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation. <i>Liver International</i> , 2011, 31, 561-571.                        | 3.9  | 64        |
| 11 | Senescence and immortality in hepatocellular carcinoma. <i>Cancer Letters</i> , 2009, 286, 103-113.  | 7.2  | 72        |
| 12 | Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. <i>Molecular Cancer</i> , 2009, 8, 90.                                     | 19.2 | 171       |